Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Abraxis BioScience, a fully integrated biotechnology company, has reported a net loss of $181.9 million, or $4.54 per share, for the fourth quarter of 2008, compared with a net loss of $5.2 million, or $0.13 per share, for the fourth quarter of 2007.
Subscribe to our email newsletter
Net revenue increased 1.5% to $92.2 million for the fourth quarter of 2008, compared with $90.8 million for the prior-year period.
For the full year 2008, net revenue increased 3.5% to $345.3 million, compared with $333.7 million for the prior year. The company reported a net loss of $276.8 million, or $6.91 per share, for 2008, compared with a net loss of $41.6 million, or $1.04 per share, in 2007.
Patrick Soon-Shiong, chairman and CEO of Abraxis BioScience, said: “In 2008, we made considerable achievements building our Abraxane commercial franchise on a global basis. We established a new infrastructure in Europe and launched Abraxane in the UK, Australia, India and the United Arab Emirates.
“With the early 2009 launch in Germany and approval to market Abraxane in China, Korea, together with the expected launches in the balance of the EU countries, we have substantial additional market opportunities for 2009 and beyond. Coupled with several strategic acquisitions and a reinforced infrastructure, we believe we are well poised for continued success.”